Executive Team

The primary strength of our ThromboGenics Executive Team is that it combines the weight of Big Pharma experience with the agility of New Pharma decision making and action. Successfully launching new products requires a special skill set, which many of our team members have acquired earlier in their careers. Our leadership team has respectable backgrounds in research, clinical development, commercialization, and financing that pave the way to long-term success. Our current management also serves as our Executive Committee, which is responsible for the company’s vision and strategy. Our Executive Committee meets regularly to plan and oversee the implementation of ThromboGenics’ policies.

Patrik De Haes – Chief Executive Officer

Patrik De Haes has more than 20 years of experience in the global healthcare industry, covering product development, marketing, and general management. Before joining ThromboGenics, Patrik was head of Roche’s global insulin infusion business. He was president and CEO of Disetronic Medical Systems Inc., a leading insulin infusion therapy company based in Minneapolis, Minnesota, USA. He also led the global development and commercialization of the first biotech product at Sandoz Pharma (now Novartis) in Switzerland. Patrik holds a degree in medicine from the University of Leuven.

Chris Buyse – Chief Financial Officer

Chris Buyse’s experience in international company finance and establishing best financial practices spans more than 20 years. Previously, as CFO of the Belgian biotechnology company CropDesign, he coordinated its acquisition by BASF in early 2007. Chris has also been finance director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and CFO and interim CEO of Keyware Technologies. He has also held financial positions at Spector Photo Group, Suez Lyonnaise des Eaux, and Unilever. Chris earned a master’s degree in economics from the University of Antwerp and an MBA from the Vlerick School in Ghent.